Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CLX buys ThyroTec's underactive thyroid test

This article was originally published in Clinica

Executive Summary

CLX Medical has definitively agreed to acquire ThyroTest, a rapid, point-of-care test for hypothyroidism, from the product's New Jersey-based developer, ThyroTec, in a cash-and-stock deal. Under the terms of the agreement, CLX will pay ThyroTec $750,000 in cash at closing, as well as issue convertible preferred stock to the latter. As part of the deal, ThyroTec CEO Jim Small will join CLX's board of directors. The two companies had previously inked a deal in which CLX would have gained exclusive worldwide sales and marketing rights to the FDA-cleared and CLIA-waived test (see Clinica No 1319, p 15). According to Murrieta, California-based CLX, around 45 million lab tests are carried out in the US to diagnose thyroid dysfunction. It believes ThyroTest can be "a cost-effective first step" to thyroid stimulating hormone testing.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041481

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel